Savant Capital’s Travere Therapeutics TVTX Stock Holding History

Savant Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$267K	Buy	+5,905	New	+$262K	﹤0.01%	1575

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Savant Capital's TVTX Position: Q2 2026 in Review

Savant Capital opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 5,905 shares worth $267K. The stake represents ﹤0.01% of the portfolio and ranks #1575 among its holdings.

321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Savant Capital held 5,905 shares of Travere Therapeutics worth $267K as of Q2 2026.
Travere Therapeutics was a new Savant Capital position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1575 holding.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.